PubMed

Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides.

Dallinga-Thie GM, Berk-Planken II, Bootsma AH, Jansen H; Diabetes Atorvastatin Lipid intervention (DALI) Study Group.

Diabetes Care. 2004 Jun;27(6):1358-64.PMID: 15161788 [PubMed - indexed for MEDLINE]Related articlesFree article

Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.

Le NA, Innis-Whitehouse W, Li X, Bakker-Arkema R, Black D, Brown WV.

Metabolism. 2000 Feb;49(2):167-77.PMID: 10690940 [PubMed - indexed for MEDLINE]Related articles

The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.

Diabetes Atorvastin Lipid Intervention (DALI) Study Group.

Diabetes Care. 2001 Aug;24(8):1335-41.PMID: 11473066 [PubMed - indexed for MEDLINE]Related articlesFree article

Quantitation of human apolipoprotein C-III and its subspecie by radioimmunoassay and analytical isoelectric focusing: abnormal plasma triglyceride-rich lipoprotein apolipoprotein C-III subspecie concentrations in hypertriglyceridemia.

Kashyap ML, Srivastava LS, Hynd BA, Gartside PS, Perisutti G.

J Lipid Res. 1981 Jul;22(5):800-10.PMID: 7288286 [PubMed - indexed for MEDLINE]Related articlesFree article

Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.

Marcoux C, Tremblay M, Fredenrich A, Davignon J, Cohn JS.

Metabolism. 2001 Jan;50(1):112-9.PMID: 11172484 [PubMed - indexed for MEDLINE]Related articles

Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.

Chan DC, Watts GF, Ooi EM, Ji J, Johnson AG, Barrett PH.

Arterioscler Thromb Vasc Biol. 2008 Oct;28(10):1831-7. Epub 2008 Jun 19.PMID: 18566295 [PubMed - indexed for MEDLINE]Related articlesFree article

Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.

Kappelle PJ, Zwang L, Huisman MV, Banga JD, Sluiter WJ, Dallinga-Thie GM, Dullaart RP.

Expert Opin Ther Targets. 2009 Jul;13(7):743-51.PMID: 19505224 [PubMed - indexed for MEDLINE]Related articles

Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.

Hogue JC, Lamarche B, Deshaies Y, Tremblay AJ, Bergeron J, Gagné C, Couture P.

Metabolism. 2008 Feb;57(2):246-54.PMID: 18191056 [PubMed - indexed for MEDLINE]Related articles

Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Témoins sur 'Infarctus du Myocarde.

Luc G, Fievet C, Arveiler D, Evans AE, Bard JM, Cambien F, Fruchart JC, Ducimetiere P.

J Lipid Res. 1996 Mar;37(3):508-17.PMID: 8728314 [PubMed - indexed for MEDLINE]Related articlesFree article

Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes.

Pontrelli L, Parris W, Adeli K, Cheung RC.

Metabolism. 2002 Mar;51(3):334-42.PMID: 11887170 [PubMed - indexed for MEDLINE]Related articles

Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders.

Onat A, Hergenç G, Sansoy V, Fobker M, Ceyhan K, Toprak S, Assmann G.

Atherosclerosis. 2003 May;168(1):81-9.PMID: 12732390 [PubMed - indexed for MEDLINE]Related articles

Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans: in vivo evidence for a link between HDL apoC-III and apoA-I metabolism.

Cohn JS, Batal R, Tremblay M, Jacques H, Veilleux L, Rodriguez C, Mamer O, Davignon J.

J Lipid Res. 2003 Oct;44(10):1976-83. Epub 2003 Jul 16.PMID: 12867543 [PubMed - indexed for MEDLINE]Related articlesFree article

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.

Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM.

JAMA. 1996 Jan 10;275(2):128-33.PMID: 8531308 [PubMed - indexed for MEDLINE]Related articles

Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients.

Parhofer KG, Laubach E, Barrett PH.

J Lipid Res. 2003 Jun;44(6):1192-8. Epub 2003 Apr 1.PMID: 12671031 [PubMed - indexed for MEDLINE]Related articlesFree article

Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients.

Lemieux I, Salomon H, Després JP.

Ann Med. 2003;35(6):442-8.PMID: 14572169 [PubMed - indexed for MEDLINE]Related articles

Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins.

Le NA, Gibson JC, Ginsberg HN.

J Lipid Res. 1988 May;29(5):669-77.PMID: 3411241 [PubMed - indexed for MEDLINE]Related articlesFree article

Role of plasma adiponectin on the HDL-cholesterol raising effect of atorvastatin in patients with type 2 diabetes.

van Hoek M, van Tol A, van Vark-van der Zee LC, Jansen H, Kastelein JJ, Sijbrands EJ, Dallinga-Thie GM.

Curr Med Res Opin. 2009 Jan;25(1):93-101.PMID: 19210142 [PubMed - indexed for MEDLINE]Related articles

Apolipoprotein C-III, hypertriglyceridemia and triglyceride-rich lipoproteins in uremia.

Moberly JB, Attman PO, Samuelsson O, Johansson AC, Knight-Gibson C, Alaupovic P.

Miner Electrolyte Metab. 1999 Jul-Dec;25(4-6):258-62.PMID: 10681649 [PubMed - indexed for MEDLINE]Related articles

Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics.

Chan DC, Watts GF, Nguyen MN, Barrett PH.

Arterioscler Thromb Vasc Biol. 2006 Mar;26(3):590-6. Epub 2006 Jan 12.PMID: 16410456 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels.

Alaupovic P, Heinonen T, Shurzinske L, Black DM.

Atherosclerosis. 1997 Aug;133(1):123-33.PMID: 9258416 [PubMed - indexed for MEDLINE]Related articles